HomeAI · summaries
Storia in 3 fonti
Merck's Welireg-Keytruda pairing sticks the landing in adjuvant kidney cancer treatment with new FDA nod
Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | The FDA approval clears Welireg's use with Keytruda in earlier-stage kidney cancer, following its 2023 solo nod for advanced disease.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan),…
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain…
- ·
endpoints.news
FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
Merck wins FDA approval for Welireg+Keytruda in adjuvant clear cell kidney cancer, after study showed a 28% risk reduction vs. Keytruda alone.
- ·
fiercepharma.com
Merck's Welireg-Keytruda pairing sticks the landing in adjuvant kidney cancer treatment with new FDA nod
Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | The FDA approval clears Welireg's use with Keytruda in…